BRIEF published on 03/24/2025 at 08:35, 1 year 7 months ago Abivax Publishes its Financial Results for 2024 Financial Results Biotechnology Research And Development Treasury Clinical Trials
PRESS RELEASE published on 03/24/2025 at 08:30, 1 year 7 months ago Abivax Announces Full Year 2024 Financial Results Abivax announces full year 2024 financial results, cash balance of EUR 144.2M, ABTECT trial progress. CEO optimistic about 2025 milestones and financial outlook Financial Results Cash Position Abivax ABTECT Trial Clinical Progress
BRIEF published on 03/14/2025 at 15:21, 1 year 7 months ago JP Morgan Chase Reduces Stake in ABIVAX Actions Abivax Regulation Threshold Crossing JP Morgan Chase
BRIEF published on 03/13/2025 at 12:43, 1 year 7 months ago JP Morgan Crosses Threshold in ABIVAX Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF published on 02/25/2025 at 18:05, 1 year 8 months ago ABIVAX: Information on capital and voting rights as of January 31, 2025 Euronext Paris Share Capital Voting Rights Abivax Finances
BRIEF published on 02/21/2025 at 08:35, 1 year 8 months ago Abivax to Hold Expert Webcast on Ulcerative Colitis Abivax Obefazimod Ulcerative Colitis Clinical Trial Webcast Event
PRESS RELEASE published on 02/21/2025 at 08:30, 1 year 8 months ago Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Abivax to host Key Opinion Leader (KOL) webcast featuring Dr. David Rubin on March 17, 2025, discussing ulcerative colitis treatment landscape and ABTECT Phase 3 Trial Abivax Ulcerative Colitis Webcast ABTECT Phase 3 Trial Key Opinion Leader
BRIEF published on 02/18/2025 at 10:08, 1 year 8 months ago Crossing of threshold at ABIVAX: statement from Sofinnova Voting Rights Abivax Threshold Crossing Product Development Sofinnova Partners
BRIEF published on 01/28/2025 at 08:35, 1 year 9 months ago Abivax unveils its financial calendar for 2025 Financial Results Biotechnology Half-yearly Report Financial Calendar Abivax
PRESS RELEASE published on 01/28/2025 at 08:30, 1 year 9 months ago Abivax Publishes 2025 Financial Calendar Abivax publishes its 2025 financial calendar, detailing key financial communications throughout the year. The company is focused on developing therapies for chronic inflammatory diseases Biotechnology Abivax Therapeutics Chronic Inflammatory Diseases 2025 Financial Calendar
Published on 10/30/2026 at 23:35, 2 days 6 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 6 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 10 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 14 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 19 hours 9 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 1 day ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 13 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 6 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 6 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 11 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 17 hours ago Capital increase through exercise of subscription rights
